MRI Contrast Problems May Be The Result of Gadolinium Toxicity
Following an MRI with contrast, if you or a loved one have suffered from persistent pain, headaches, skin changes, brain fog or other problems, it may be the result of toxic gadolinium building up in your brain or body.
Gadolinium is used to help enhance images during an MRI or MRA exam. While patients are told that the contrast dye is safe and leaves the body within a few days if you have normal kidney function, mounting evidence suggests that is not the case and gadolinium may be retained, posing serious health risks.
The lawyers at Saiontz & Kirk, P.A. are reviewing potential MRI gadolinium toxicity lawsuits for individuals who have experienced any of the following symptoms within a few weeks after an exam where a contrast dye was injected:
- Persistent Headaches
- Bone and Joint Pain
- Reduced Cognitive Function
- Tendon and Ligament Pain
- Thickening Of Soft Tissues
- Nephrogenic Systemic Fibrosis
Gadolinium Retention from MRI Contrast Dye
About ten years ago, our law firm represented individuals nationwide who were diagnosed nephrogenic systemic fibrosis from MRI contrast agents.
This debilitating and life-threatening condition was seen among individuals with impaired kidney function, where the contrast dye was not being excreted from the body, resulting in gadolinium toxicity.
Although the manufacturers have maintained that gadolinium MRI contrast dye is safe for individuals with normal kidney function, recent evidence indicates that gadolinium may be retained in the body and brain.
- March 2015 – A study published in the medical journal Radiology found evidence of gadolinium deposits in the brain of those who had an MRI with contrast, while those who had not received the injections did not have the residue.
- June 2015 – The findings of research conducted on the rats was published in the journal Investigative Radiology, indicating that animals injected with “linear” gadolinium contrast agents had high levels of gadolinium deposits deep in the brain, with significant and persistent abnormalities, as well as signs of hyperintensity even after injections were stopped.
- July 2015 – FDA announces that it is evaluating the risk of gadolinium brain deposits from repeated MRI contrast exams, following recent publications in medical literature.
- July 2016 – American College of Radiology updates guidelines for when to use gadolinium MRI dye, including factors that should now be considered based on the risk of deposits in the brain or other sensitive organs.
- September 2017 – The FDA Medical Imagine Drugs Advisory Committee voted 13-1 to recommend new MRI contrast dye warnings about the risk of gadolinium buildup in the brain.
- December 2017 – New gadolinium warnings were announced by the FDA about the risk of gadolinium retention, and new recommendations for healthcare professionals and patients.
Gadolinium Toxicity Lawyers
As a result of the failure to warn about the risks associated with gadolinium deposits building up in the brain and body, the lawyers at Saiontz & Kirk, P.A. are reviewing potential injury cases for individuals nationwide.
Financial compensation may be available for individuals who have suffered side effects from gadolinium toxicity. The progressive disease may have been avoided if patients and doctors had been informed about the potential risk before agreeing to undergo an MRI with contrast.
All claims are handled by our lawyers on a contingency fee basis, meaning there is no fee unless a recovery is obtained. To review a potential claim, request a free consultation and claim evaluation.